Foundayo (Orforglipron) for Lifters: What the GLP-1 Pill Means for Muscle

Collage of a hand holding a single plain white tablet in front of a dumbbell, with the headline "The GLP-1 Pill"

Foundayo (orforglipron) is a once-daily GLP-1 tablet that the FDA approved on April 1, 2026 for adults with obesity, or with overweight plus a weight-related condition. In its main trial, people on the top strength lost about 11% of their body weight over 72 weeks, and a small scan substudy pooling all three doses found that roughly a quarter of the weight lost was lean mass. A pill removes the needle, but it does not remove the need to lift and eat enough protein.

This article is general education and not medical advice. Foundayo is a prescription drug with a boxed warning and real side effects. Whether it suits you, at what dose, and how to train while taking it are decisions for your own prescriber, with a pharmacist or registered dietitian helping on the details.

What the FDA approved, and who it is for

The FDA's announcement and the prescribing information describe Foundayo as a GLP-1 receptor agonist taken as a tablet once a day, alongside a reduced-calorie diet and more physical activity. It is indicated to reduce excess body weight and keep it off long term in adults with obesity, or in adults with overweight who have at least one weight-related condition. In the main trial, that meant a BMI of 30 or more, or a BMI from 27 to under 30 plus a condition such as high blood pressure, abnormal blood fats or sleep apnea.

The label allows the tablet with or without food and does not recommend combining it with another GLP-1 drug. Safety and effectiveness have not been established in children. It is not the first GLP-1 pill for weight management: Novo Nordisk's Wegovy pill (oral semaglutide) was approved on December 22, 2025. And it is not a cosmetic tool for people at a normal weight who want to look leaner; none of the data below speaks to that use.

What the main trial showed

The evidence base is ATTAIN-1, a 72-week, double-blind, placebo-controlled phase 3 trial (Wharton et al., New England Journal of Medicine, September 2025). It randomized 3,127 adults with obesity, or overweight plus a complication, and without diabetes. Everyone received lifestyle counseling. Lilly funded the trial, and its sponsor analyzed the data.

The trial doses were 6, 12 and 36 mg of an investigational capsule. The FDA label reports this trial as equivalent doses of the final tablet, 5.5, 9 and 17.2 mg, and a published bioequivalence study pairs those capsule and tablet strengths in the same order, so the 36 mg arm in the paper corresponds to the 17.2 mg tablet. Average weight change at week 72, counting everyone randomized:

  • Lowest dose arm: 7.5% loss
  • Middle dose arm: 8.4% loss
  • Highest dose arm: 11.2% loss
  • Placebo: 2.1% loss

The label's table rounds slightly differently (11.1% for the top dose) but tells the same story. Average starting weight was about 103 kg, so 11% is roughly 11 kg, or about 25 pounds, for the average person on the top strength, against about 2 kg on placebo. That is arithmetic on averages, not a prediction for you.

Averages hide a wide spread. On the highest dose, 54.6% of participants lost at least 10% of body weight and 18.4% lost at least 20%, compared with 12.9% and 2.8% on placebo, and the paper notes that responses varied substantially. The 12.4% figure you may see quoted comes from the efficacy estimand, which the paper describes as the effect if every participant had taken the drug as intended. The primary analysis gave 11.2%. When you compare this pill with any other drug, check that the analysis rules and the populations match; Novo Nordisk's 16.6% for the Wegovy pill, for example, comes from a different trial.

Muscle loss on this pill: what is known and what is not

What is known

The ATTAIN-1 paper includes a body-composition subgroup of 171 participants who had DXA scans. In the pooled orforglipron groups, total fat mass fell by a mean of 13.8%, visceral fat by 19.0% and lean mass by 4.5% at week 72. In the placebo group, fat mass fell by 1.7%, while lean mass rose by 0.3% and visceral fat rose by 7.4%. The authors calculated that 73.1% of the weight lost on the drug was fat and 26.9% was lean mass. The label's pharmacology section agrees in general terms: weight falls with a greater loss of fat mass than lean mass.

Here is illustrative arithmetic, not trial data. If you lose 10 kg and 27% of it is lean tissue, that is 2.7 kg. If you start with 60 kg of lean mass, a 4.5% drop is also 2.7 kg. Small in percentage terms, but worth watching if some of it is muscle you train with.

For scale, a DXA substudy of the injectable tirzepatide in SURMOUNT-1 (Look et al., Diabetes, Obesity and Metabolism, 2025; 160 participants) reported roughly 75% of weight lost as fat and 25% as lean mass, with similar proportions on placebo. The pill's split is in the same range. But the drugs and populations differ and the studies were not built to be compared, so this is context, not a ranking of which medication is kinder to muscle.

What is not known

  • The sample is small. The scan subgroup was 171 of 3,127 participants, under 6%, and the paper's text reports the three doses pooled.
  • DXA lean mass is not muscle. It includes water, organs and connective tissue as well as muscle, and the paper reports no grip or leg-strength test.
  • Nobody was told to lift. Participants got diet and physical-activity counseling (the label cites a recommended minimum of 150 minutes a week). With no resistance-training arm, ATTAIN-1 cannot say whether lifting changes the lean-mass share on this drug.
  • The participants were not lean lifters. Average body weight was about 103 kg and average BMI about 37. There are no data here for already-muscular or already-lean people.
  • Longer horizons are open. The trial covers 72 weeks. For what happens after treatment ends, see weight regain and lifting after you stop a GLP-1.

So the scan data for this pill look broadly like what has been reported for injectables, but they are thin, and nothing here shows the pill spares muscle by itself. Where injectable data appear in this article they are background, not proof about this tablet.

What a pill changes for lifters, and what it does not

The label says the drug's weight effect is likely mediated by decreased appetite, the same lever the injectables pull. The lifter's problem is therefore the same: less food means less protein and less energy for training and recovery unless you plan for it. The label also notes that the tablet delays gastric emptying, with the delay largest after the first dose and shrinking over time, and that this has the potential to affect how other oral medicines are absorbed, so tell your pharmacist about everything you take, supplements included.

What changes is convenience; the ATTAIN-1 authors note that oral agents may be easier to store and administer than injections. For training, the plan is the one in our guide to lifting on Ozempic, Wegovy or Zepbound. That guide was written around injectables, so treat the carry-over to this pill as reasoned rather than proven. Lifting is also associated with lower mortality risk in observational research, which we cover in our post on strength training and mortality risk.

A protein and training template while on a GLP-1

Use this only after your prescriber has cleared you to exercise, and scale it back on days when nausea or low energy hit.

Protein

A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society (published in several journals, including Obesity) notes that targets of 1.2 to 1.6 g of protein per kg per day have been proposed during active weight loss, and offers an absolute target of 80 to 120 g a day as an alternative that may be easier to stick to. It says it is unclear whether the kilograms should be based on actual weight, adjusted weight or fat-free mass, and that using actual weight can significantly overestimate protein needs in people with obesity.

Our post on how much protein you need for muscle gains uses a higher range, 1.6 to 2.2 g/kg, which suits lean people training hard without an appetite suppressant. On a GLP-1, the advisory's range is a reasonable starting point to discuss with your dietitian, who can also say whether to aim higher. At 90 kg, 1.2 to 1.6 g/kg is 108 to 144 g a day, which at the top end runs past the advisory's 80 to 120 g target, so ask your dietitian which number to use. Split four ways, that is roughly 27 to 36 g per feeding. Put protein first in the meal, as the advisory suggests, and use liquid protein when solid food is unappealing.

Training

The advisory aims for strength training at least three times a week plus at least 150 minutes of moderate-intensity aerobic activity a week. If that is too much on day one, two full-body sessions a week is a defensible start. Alternate these:

Do 2 to 3 sets of 6 to 12 reps on each lift and stop with about two reps still in the tank. Add reps first, then weight once you reach the top of the range. For how much volume is enough, see how many sets you need for muscle growth. If a session leaves you queasy or lightheaded, cut sets rather than skipping the week.

Safety: who should not take it, and when to stop training

This section summarizes the FDA prescribing information. It does not replace the full label or your prescriber.

Who it is not for, and what your clinician decides

  • Thyroid history. The label carries a boxed warning about thyroid C-cell tumors and contraindicates the drug with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It also states that orforglipron did not cause tumors in rodents and that the human relevance of the class signal has not been determined.
  • Pregnancy. The label says the drug may cause fetal harm and to stop it when pregnancy is recognized. If you take oral contraceptives, it advises a non-oral or barrier method for 30 days after starting and after each dose increase.
  • Other conditions. Serious hypersensitivity to the drug is a contraindication. Use is not recommended in severe gastroparesis or severe liver impairment. Insulin or sulfonylurea use raises hypoglycemia risk, so those doses may need to change.
  • Surgery. Tell the team about any planned procedure under anesthesia or deep sedation; the label flags an aspiration risk with GLP-1 drugs. That matters if a training injury might lead to surgery.
  • Dose and source. Never adjust the dose yourself, and get the drug only from a licensed prescriber and pharmacy.

Side effects that touch training

At the highest strength in the two pooled label trials, which included people with type 2 diabetes, nausea affected 35% of people (10% on placebo), diarrhea 25% (11%), vomiting 24% (4%) and constipation 24% (9%). Nausea, vomiting and diarrhea were more frequent while the dose was being raised and decreased over time. Across all strengths, 8% stopped because of side effects, against 3% on placebo.

Three findings matter under a barbell. Hypotension was reported in 2% of people on the drug versus 0.5% on placebo, and in 4% of those also taking blood pressure medicine. Average heart rate rose by 4 to 5 beats per minute, which matters if you train by wearable heart-rate zones. Hair loss was associated with weight reduction and reported in 7% of women versus 0.9% of men on the drug.

Red flags

Stop training and contact a clinician for severe or persistent abdominal pain (possible pancreatitis or gallbladder disease), repeated vomiting or diarrhea with dizziness or little urine (dehydration can injure the kidneys), a lump in the neck, trouble swallowing or persistent hoarseness. Swelling of the face or throat, or trouble breathing, needs emergency care. Skip hard sessions on days with vomiting or diarrhea and rehydrate first.

Common mistakes

  • Treating the pill as the whole plan. The approved use is alongside a reduced-calorie diet and more physical activity, and the trial did not test strength training.
  • Letting protein slide. Fullness arrives early, and protein quietly drops if you do not count it somewhere.
  • Watching only the scale. Scale weight cannot tell fat from lean mass. Your lifts add information.
  • Using it as a cutting aid. It was studied in people with obesity or overweight plus a condition, not in lean lifters.

Tracking strength while the scale drops

The one thing you can measure yourself is whether your lifts hold. Write down weight, reps and sets for the same few exercises each session, and compare four-week blocks rather than single days. Use a weekly average body weight, and log protein separately. A rule of thumb, not a validated threshold: if your main lifts fall for three or four weeks despite good sleep and food, take the log to your clinician or dietitian.

Easy Reps is a free iPhone workout tracker with no account and no ads. Its workout history keeps every set, you can filter by exercise, and estimated one-rep max updates on its own, so a strength trend over a few months is easy to see; the features page has the details. It does not log nutrition or body measurements, so protein and body weight go in whatever you already use.

Bottom line

Foundayo is an approved once-daily GLP-1 tablet that produced about 11% average weight loss at 72 weeks on the top strength in a large trial, with side effects typical of the class. The only body-composition data are a 171-person DXA subgroup in which about 27% of the weight lost was lean mass, a share that resembles what has been reported for an injectable but says nothing about lifting, strength or lean people. Plan on the same basics as with any GLP-1: enough protein across the day, strength training two to three times a week to start (the advisory aims for at least three), and a log that shows whether your strength holds. Whether to take the drug, and how to train on it, is a decision for you and your prescriber.

Sources